So Shel-Bot is 4 for 5 on earnings picks for the week so far and that means this is a project we will continue to work on. He's getting better and better at analyzing companies and I'm especially liking our now-famous "The Good, the Bad and the Ugly" reports he's been producing as it has really helped us focus on what's happening after the earnings reports are turned in.
For instance, on BNTX, who I think are worth a toss down here. Here's is Shel-Bot's regular report on the earnings:
⊗Hello, this is Bing. According to the finance results 1, BioNTech SE (BNTX) reported its Q1 2023 earnings on May 8, 2023. Here are some of the main highlights and analysis:
-
- BioNTech reported total revenue of $1.277 billion for Q1 2023, a decrease of 70% compared to Q4 2022, but an increase of 7,344% compared to Q1 2022 1. The revenue was mainly driven by the sales of its COVID-19 vaccine Comirnaty, which it co-developed with Pfizer. The company recognized $1.235 billion of its share of gross profit from the vaccine sales in Q1 2023 1.
- BioNTech reported a net profit of $48 million for Q1 2023, a decrease of 98% compared to Q4 2022, but an increase of 2,400% compared to Q1 2022 1. The net profit margin was 3.8% for Q1 2023, down from 79.5% for Q4 2022 and up from -0.2% for Q1 2022 1. The company attributed the lower profitability to higher R&D expenses, higher taxes, and lower gross margin from the vaccine sales 2.
- BioNTech reported a basic earnings per share (EPS) of $0.194 for Q1 2023, a decrease of 98% compared to Q4 2022, but an increase of 2,370% compared to Q1 2022 1. The EPS was below the consensus estimate of -$0.53 1.
